A Study of a Rilpivirine Extended-Release Suspension in Healthy Participants
Study Details
Study Description
Brief Summary
The purpose of this study is to characterize the single dose pharmacokinetics (PK) and evaluate the safety and tolerability of subcutaneous administration of rilpivirine (RPV) long-acting (LA) or RPV LA in combination with cabotegravir (CAB) LA extended release suspensions in different conditions in healthy adult participants.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Panel A: Rilpivirine (RPV) Long-acting (LA) Participants will receive one dose of RPV LA (formulation 1) under different conditions (Treatment A and B) on Day 1. |
Drug: RPV LA
RPV LA will be administered at different formulations.
Other Names:
|
| Experimental: Panel B: RPV LA Participants will receive one dose of RPV LA (formulation 2) under different conditions (Treatment C and D) on Day 1. |
Drug: RPV LA
RPV LA will be administered at different formulations.
Other Names:
|
| Experimental: Panel C: RPV LA Participants will receive one dose of RPV LA (formulation 1) under different conditions (Treatment E and F) on Day 1, based on interim data of Panel A. |
Drug: RPV LA
RPV LA will be administered at different formulations.
Other Names:
|
| Experimental: Panel D: RPV LA Participants will receive one dose of RPV LA (formulation 2) under different conditions (Treatment G and H) on Day 1, based on interim data of Panel B. |
Drug: RPV LA
RPV LA will be administered at different formulations.
Other Names:
|
| Experimental: Panel E: RPV LA + Cabotegravir (CAB) LA Participants will receive one dose of RPV LA (formulation 1) with CAB LA (formulation 3) (Treatment I) on Day 1. |
Drug: RPV LA
RPV LA will be administered at different formulations.
Other Names:
Drug: CAB LA
CAB LA will be administered at formulation 3.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Plasma Concentration of Rilpivirine (RPV) [Up to 72 weeks]
Plasma samples will be analyzed to determine concentrations of RPV using a validated, specific, and sensitive method.
- Plasma Concentration of Cabotegravir (CAB) [Up to 72 weeks]
Plasma samples will be analyzed to determine concentrations of CAB using a validated, specific, and sensitive method.
Secondary Outcome Measures
- Number of Participants With Adverse Events (AEs) [Up to 72 weeks]
An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/ biological agent under study.
- Number of Participants with Injection-Site Reactions [Up to 72 weeks]
Number of participants with injection-site reactions will be reported. A study intervention injection-site reaction is any adverse reaction at a subcutaneous study intervention injection-site.
- Number of Participants with Abnormalities in 12-Lead Electrocardiograms (ECGs) [Up to 72 weeks]
Number of participants with abnormalities in 12- lead ECGs (heart rate, PR, QRS and QT corrected [QTc]) will be reported.
- Pain Assessment using Visual Analogue Scale (VAS) [Up to 72 weeks]
Pain assessments will be performed by collecting pain intensity scores using 100-millimetre (mm) VAS.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Participant must be healthy on the basis of physical examination, medical history, vital signs, and 12-lead electrocardiogram (ECG) (based on the average value of triplicate ECGs) performed at screening (results must be available on Day -1)
-
Participant must be healthy on the basis of clinical laboratory tests performed at screening (results must be available prior to dosing on Day 1). If there are abnormalities, the participant may be included only if the investigator judges the abnormalities or deviations from normal to be not clinically significant. This determination must be recorded in the participant's source documents and initialed by the investigator
-
All women participants must have a negative highly sensitive serum (Beta-human chorionic gonadotropin [Beta-hCG]) pregnancy test at screening and on Day -1
-
A woman must agree not to donate eggs (ova, oocytes) or freeze for future use for the purposes of assisted reproduction during the study and for at least 72 weeks after receiving the dose of study intervention
-
A male participant (not vasectomized) who is heterosexually active with a woman of childbearing potential must agree to use two effective contraceptive methods for the duration of the study (72 weeks follow-up), or for at least 72 weeks after receiving the dose of study intervention for those who do not complete the study
Exclusion Criteria:
-
Participant with a history of or current illness that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study intervention to the participant or that could prevent, limit or confound the protocol specified assessments. This may include, but is not limited to, hepatic or renal dysfunction, cardiac disease, vascular, significant pulmonary disease, including bronchospastic respiratory disease, diabetes mellitus, neurologic, hematologic, coagulation disorders (including any abnormal bleeding or blood dyscrasias), or psychiatric disturbances
-
Participant has a history of malignancy within 5 years before screening (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or malignancy, which is considered cured with minimal risk of recurrence)
-
Participant has known allergies, hypersensitivity, or intolerance to Cabotegravir (CAB) or its excipients
-
Participants with the following ECG findings, if clinically significant: abnormal PR, QRS, and QTc intervals; rhythm abnormalities; evidence of acute ischemic changes
-
Participants with a history of clinically relevant skin disease such as, but not limited to, dermatitis, eczema, drug rash, drug allergy, psoriasis, food allergy, urticaria
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | PRA Health Sciences | Lenexa | Kansas | United States | 66219 |
| 2 | PRA Health Sciences | Salt Lake City | Utah | United States | 84124 |
| 3 | PRA Health Sciences | Groningen | Netherlands | NZ 9728 |
Sponsors and Collaborators
- Janssen Research & Development, LLC
Investigators
- Study Director: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- CR109089
- TMC278LAHTX1003
- 2021-002697-31